KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib - PubMed (original) (raw)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
William Pao et al. PLoS Med. 2005 Jan.
Abstract
Background: Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive.
Methods and findings: We sought to determine whether mutations in KRAS could be used to further enhance prediction of response to gefitinib or erlotinib. We screened 60 lung adenocarcinomas defined as sensitive or refractory to gefitinib or erlotinib for mutations in EGFR and KRAS. We show that mutations in KRAS are associated with a lack of sensitivity to either drug.
Conclusion: Our results suggest that treatment decisions regarding use of these kinase inhibitors might be improved by determining the mutational status of both EGFR and KRAS.
Conflict of interest statement
Competing Interests: VAM has received research funding from Genentech (co-developer of erlotinib). He has received honoraria from AstraZeneca (maker of gefitinib) for consultancy. MGK has received research funding from AstraZeneca and research funding and consulting fees from Genentech and has represented AstraZeneca before the US Food and Drug Administration. WP, VAM, MFZ, and HEV, represented by the Sloan-Kettering Institute for Cancer Research, filed on June 1, 2004, a provisional patent application entitled “Use of mutations in EGFR kinase as an indicator of therapeutic efficacy of erlotinib in the treatment of NSCLC,” serial number 60/576,275. HEV is Co-founder and Chair of the Board of Directors of the Public Library of Science.
Figures
Figure 1. Sequence Chromatograms Displaying the Types of KRAS Mutations Found in This Study
Comment in
- Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy.
Inoue A, Nukiwa T. Inoue A, et al. PLoS Med. 2005 Jan;2(1):e13. doi: 10.1371/journal.pmed.0020013. PLoS Med. 2005. PMID: 15696203 Free PMC article. Review.
Similar articles
- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article. - Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Suda K, et al. J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52. J Thorac Oncol. 2011. PMID: 21597390 - Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y. Kondo M, et al. Lung Cancer. 2005 Dec;50(3):385-91. doi: 10.1016/j.lungcan.2005.06.008. Epub 2005 Sep 2. Lung Cancer. 2005. PMID: 16140420 - Factors predicting response to EGFR tyrosine kinase inhibitors.
Engelman JA, Jänne PA. Engelman JA, et al. Semin Respir Crit Care Med. 2005 Jun;26(3):314-22. doi: 10.1055/s-2005-871990. Semin Respir Crit Care Med. 2005. PMID: 16052433 Review. - Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X, Chang A. Zhang X, et al. J Med Genet. 2007 Mar;44(3):166-72. doi: 10.1136/jmg.2006.046102. Epub 2006 Dec 8. J Med Genet. 2007. PMID: 17158592 Free PMC article. Review.
Cited by
- Co-freezing localized CRISPR-Cas12a system enables rapid and sensitive nucleic acid analysis.
Zhang L, Luo S, Li W, Su W, Chen S, Liu C, Pan W, Situ B, Zheng L, Li L, Yan X, Zhang Y. Zhang L, et al. J Nanobiotechnology. 2024 Oct 5;22(1):602. doi: 10.1186/s12951-024-02831-8. J Nanobiotechnology. 2024. PMID: 39367442 Free PMC article. - Clinical applications of circulating biomarkers in non-small cell lung cancer.
Oh HJ, Imam-Aliagan AB, Kim YB, Kim HJ, Izaguirre IA, Sung CK, Yim H. Oh HJ, et al. Front Cell Dev Biol. 2024 Aug 21;12:1449232. doi: 10.3389/fcell.2024.1449232. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39239557 Free PMC article. Review. - Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomes.
Truesdell P, Chang J, Coto Villa D, Dai M, Zhao Y, McIlwain R, Young S, Hiley S, Craig AW, Babak T. Truesdell P, et al. NPJ Precis Oncol. 2024 Aug 28;8(1):186. doi: 10.1038/s41698-024-00673-z. NPJ Precis Oncol. 2024. PMID: 39198692 Free PMC article. - Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.
He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X. He J, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):209. doi: 10.1038/s41392-024-01891-4. Signal Transduct Target Ther. 2024. PMID: 39138145 Free PMC article. Review.
References
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. - PubMed
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
- Stephens P, Hunter C, Bignell G, Edkins S, Davies H, et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431:525–526. - PubMed
- Rodenhuis S, Slebos RJC, Boot AJM, Evers SG, Mooi WJ, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738–5741. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous